A Comparison of Topical Dorzolamide and Topical Nevanac in the Treatment of Central Serous Retinopathy: A Prospective Clinical Study
European Journal of Molecular & Clinical Medicine,
2021, Volume 8, Issue 3, Pages 4259-4263
AbstractAim: To compared the efficacy of topical dorzolamide and topical nevanac in central serous retinopathy.
Methods: This prospective study was carried out in the Department of Ophthalmology, Madhubani Medical College and Hospital, Madhubani, Bihar, India for 1 year. Total 20 patients diagnosed with acute CSR were included in this study. Patients divided into 2 equal groups, diagnosed with acute CSR relying upon visual acuity, dilated fundus examination and OCT findings. A detailed history of all the patients was taken to rule out other etiologies. Vision and central macular thickness were recorded using standard Snellen chart and optical coherence tomography respectively (OCT).
Results: On examination of group A patient, had visual acuity of 6/60, Counting fingers at 4 meters in the Right eye respectively, and central macular thickness (CMT) on OCT 420 microns to 430 microns respectively and group B Patient had a visual acuity of 6/60 in right eye and had a visual acuity of 6/60 in left eye, and central macular thickness on OCT was 433 microns to 457 microns respectively. Group A were started on Nevanac eye drops thrice daily, and Group B on Dorzolamide eye drops twice daily. All the patients were followed up on the 1st, 2nd, 3rd and 4th week. On each visit, vision, dilated fundoscopy, and OCT were performed. On follow up at 1st, 2nd, 3rd and 4th week it was observed that macular thickness in Group B reduced on a faster rate than in Group A
Conclusion: The two topical medications, i.e., nevanac and dorzolamide, to which both the patients responded well. But it was more rapid in the case of patient treated with dorzolamide.
- Article View: 139
- PDF Download: 600